A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy

Takayuki Takahashi, Masato Fujisaki, Shinobu Hirahata, Dai Maeda, Hideyuki Tokura, Takashi Ohyama, Tomoyuki Irino

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We report herein a case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP/Lentinan combination chemotherapy. A 74-year-old male suffering from anorexia was admitted to our hospital and diagnosed as having type 2 gastric cancer metastasizing to the liver. TS-1 was orally administered at 100 mg/body/day for 28 days with a 14-day interval as one session. During the second session, because grade 1 thrombocytopenia was noted, administration of TS-1 was rescheduled to every other day. CDDP was infused at 10 mg/body/day on day 6 to 10, 13, 15, and 17. After his discharge, CDDP at 10 mg/body and Lentinan at 2 mg/body were weekly infused as ambulant patient chemotherapy. The abdominal CT scan showed reduction of hepatic tumors by 86% in three months and 97% in 16 months. Metastatic lymph nodes disappeared in 4 months. The primary tumor was reduced and flattened to a cicatrix, and endoscopic biopsy revealed no cancer cells. The tumor markers, CEA (716.9 ng/ml) and CA 19-9 (57.2 U/ml), were reduced to normal range. The therapeutic efficacy was judged as a partial response (PR), which lasted for 16 months without severe adverse effects. He maintained good quality of life. This combination chemotherapy was thought to be beneficial for patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)2061-2063
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number13
Publication statusPublished - 2006 Jan 1
Externally publishedYes

Fingerprint

Lentinan
Combination Drug Therapy
Stomach Neoplasms
Neoplasm Metastasis
Liver
Neoplasms
Anorexia
Tumor Biomarkers
Psychological Stress
Cicatrix
Reference Values
Lymph Nodes
Quality of Life
Biopsy
Drug Therapy
titanium silicide
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy. / Takahashi, Takayuki; Fujisaki, Masato; Hirahata, Shinobu; Maeda, Dai; Tokura, Hideyuki; Ohyama, Takashi; Irino, Tomoyuki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 33, No. 13, 01.01.2006, p. 2061-2063.

Research output: Contribution to journalArticle

Takahashi, T, Fujisaki, M, Hirahata, S, Maeda, D, Tokura, H, Ohyama, T & Irino, T 2006, 'A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 33, no. 13, pp. 2061-2063.
Takahashi, Takayuki ; Fujisaki, Masato ; Hirahata, Shinobu ; Maeda, Dai ; Tokura, Hideyuki ; Ohyama, Takashi ; Irino, Tomoyuki. / A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; Vol. 33, No. 13. pp. 2061-2063.
@article{aa421d89bd4d436c88b392786a635ede,
title = "A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy",
abstract = "We report herein a case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP/Lentinan combination chemotherapy. A 74-year-old male suffering from anorexia was admitted to our hospital and diagnosed as having type 2 gastric cancer metastasizing to the liver. TS-1 was orally administered at 100 mg/body/day for 28 days with a 14-day interval as one session. During the second session, because grade 1 thrombocytopenia was noted, administration of TS-1 was rescheduled to every other day. CDDP was infused at 10 mg/body/day on day 6 to 10, 13, 15, and 17. After his discharge, CDDP at 10 mg/body and Lentinan at 2 mg/body were weekly infused as ambulant patient chemotherapy. The abdominal CT scan showed reduction of hepatic tumors by 86{\%} in three months and 97{\%} in 16 months. Metastatic lymph nodes disappeared in 4 months. The primary tumor was reduced and flattened to a cicatrix, and endoscopic biopsy revealed no cancer cells. The tumor markers, CEA (716.9 ng/ml) and CA 19-9 (57.2 U/ml), were reduced to normal range. The therapeutic efficacy was judged as a partial response (PR), which lasted for 16 months without severe adverse effects. He maintained good quality of life. This combination chemotherapy was thought to be beneficial for patients with advanced gastric cancer.",
author = "Takayuki Takahashi and Masato Fujisaki and Shinobu Hirahata and Dai Maeda and Hideyuki Tokura and Takashi Ohyama and Tomoyuki Irino",
year = "2006",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "2061--2063",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1/low-dose CDDP/lentinan combination chemotherapy

AU - Takahashi, Takayuki

AU - Fujisaki, Masato

AU - Hirahata, Shinobu

AU - Maeda, Dai

AU - Tokura, Hideyuki

AU - Ohyama, Takashi

AU - Irino, Tomoyuki

PY - 2006/1/1

Y1 - 2006/1/1

N2 - We report herein a case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP/Lentinan combination chemotherapy. A 74-year-old male suffering from anorexia was admitted to our hospital and diagnosed as having type 2 gastric cancer metastasizing to the liver. TS-1 was orally administered at 100 mg/body/day for 28 days with a 14-day interval as one session. During the second session, because grade 1 thrombocytopenia was noted, administration of TS-1 was rescheduled to every other day. CDDP was infused at 10 mg/body/day on day 6 to 10, 13, 15, and 17. After his discharge, CDDP at 10 mg/body and Lentinan at 2 mg/body were weekly infused as ambulant patient chemotherapy. The abdominal CT scan showed reduction of hepatic tumors by 86% in three months and 97% in 16 months. Metastatic lymph nodes disappeared in 4 months. The primary tumor was reduced and flattened to a cicatrix, and endoscopic biopsy revealed no cancer cells. The tumor markers, CEA (716.9 ng/ml) and CA 19-9 (57.2 U/ml), were reduced to normal range. The therapeutic efficacy was judged as a partial response (PR), which lasted for 16 months without severe adverse effects. He maintained good quality of life. This combination chemotherapy was thought to be beneficial for patients with advanced gastric cancer.

AB - We report herein a case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP/Lentinan combination chemotherapy. A 74-year-old male suffering from anorexia was admitted to our hospital and diagnosed as having type 2 gastric cancer metastasizing to the liver. TS-1 was orally administered at 100 mg/body/day for 28 days with a 14-day interval as one session. During the second session, because grade 1 thrombocytopenia was noted, administration of TS-1 was rescheduled to every other day. CDDP was infused at 10 mg/body/day on day 6 to 10, 13, 15, and 17. After his discharge, CDDP at 10 mg/body and Lentinan at 2 mg/body were weekly infused as ambulant patient chemotherapy. The abdominal CT scan showed reduction of hepatic tumors by 86% in three months and 97% in 16 months. Metastatic lymph nodes disappeared in 4 months. The primary tumor was reduced and flattened to a cicatrix, and endoscopic biopsy revealed no cancer cells. The tumor markers, CEA (716.9 ng/ml) and CA 19-9 (57.2 U/ml), were reduced to normal range. The therapeutic efficacy was judged as a partial response (PR), which lasted for 16 months without severe adverse effects. He maintained good quality of life. This combination chemotherapy was thought to be beneficial for patients with advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=33846921330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846921330&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 2061

EP - 2063

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -